Investor Overview

Corporate Profile
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has... more >
Recent Newsmore >
June 20, 2017
Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress
BRISBANE, Calif. & HELSINKI--(BUSINESS WIRE)--Jun. 20, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today reported findings from pre-randomization, preliminary clinical data collected from the European screening population of the PALISADE trial in Aimmune’s AR101 program. In addition, the company reported observations from a survey on current management and use... 
June 15, 2017
Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017
— Abstracts Report on Screening Population for PALISADE Phase 3 Clinical Trial and Current Management of Peanut Allergy — BRISBANE, California--(BUSINESS WIRE)--Jun. 15, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, announced today that it will present data during poster sessions on Tuesday, June 20, at the 2017 European Academy of Allergy and Clinical Immunolog... 
June 12, 2017
Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy
— Final Study Visits Projected Around Year-End 2017; Topline Data Expected in the First Quarter of 2018 — — More Than 97 Percent of Patients Currently On Study Are Through the Up-Dosing Phase — BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 12, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that, in the ongoing Phase 3 PALISADE trial of A... 
Upcoming Eventsmore >
There are currently no events scheduled.
Email Alerts
Sign up to receive email alerts when Aimmune Therapeutics posts new information to this site. Please enter your email address and click submit below.